Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00943293 · ClinicalTrials.gov registry record · Phase 1
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
A Phase 1 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00943293 is a Phase 1 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 1 participants.
The verdict
NCT00943293, a Phase 1 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a clinical research study designed to evaluate whether the administration of a vaccine to patients after transplant consisting of a minor histocompatibility antigen (mHag peptide) mixed with G-CSF (a drug intended to stimulate the immune system) can stimulate increased graft versus leukemia (GVL) responses without causing graft-versus-host disease (GVHD).
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG Campath
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2003-05 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00943293
The ClinicalTrials.gov registry entry for NCT00943293 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fludarabine is the first listed.
NCT00943293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00943293 about?
NCT00943293 is a clinical study titled "Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies". This is a clinical research study designed to evaluate whether the administration of a vaccine to patients after transplant consisting of a minor histocompatibility antigen (mHag peptide) mixed with G-CSF (a drug intended to stimulate the immune system) can stimulate increased graft versus leukemia ...
What is the current status of trial NCT00943293?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2003-05. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00943293?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Campath (DRUG).
Who is sponsoring clinical trial NCT00943293?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.